Central Nervous System News and Research

RSS

AACN endorses 'Adult-Gerontology Clinical Nurse Specialist Competencies'

The American Association of Critical-Care Nurses (AACN) recently endorsed the "Adult-Gerontology Clinical Nurse Specialist Competencies," developed by the American Association of Colleges of Nursing , Washington, D.C., with The Hartford Institute for Geriatric Nursing at New York University and National Association of Clinical Nurse Specialists , Philadelphia.

17 Sep 2010

AMRI selects compound for advanced preclinical testing in treatment of IBS

AMRI today announced the selection of a compound from its proprietary research program for the treatment of irritable bowel syndrome (IBS) for advanced preclinical testing, with the goal of submitting an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in 2011.

15 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

ADHD medication improves childhood cancer survivors: Research

A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children's Research Hospital investigators.

14 Sep 2010

Orion extends use of Medidata Rave enterprise-wide EDC and clinical data management system

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that European pharmaceutical company Orion has extended its use of Medidata Rave® as its enterprise-wide electronic data capture (EDC) and clinical data management (CDM) system, which Orion successfully brought in-house and deployed for all clinical trials for the past three and a half years.

13 Sep 2010

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

XenoPort, Inc. announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.

13 Sep 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010

Multi-disciplinary team awarded grant to develop interdisciplinary oncology palliative care education program

A multi-disciplinary team representing the schools of Medicine, Nursing and Social Work at the University of Louisville, as well as clinical pastoral education programs in three Louisville hospitals, has been awarded a grant of $1,518,092 from the National Institutes of Health that will fund the development, implementation and evaluation of an interdisciplinary oncology palliative care education program. Work related to the project will begin immediately.

9 Sep 2010

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET (bromocriptine mesylate) tablets in the U.S.

9 Sep 2010

Consumption of medications for treatment of insomnia or anxiety increases mortality risk

Taking medications to treat insomnia and anxiety increases mortality risk by 36%, according to a study conducted by Genevi-ve Belleville, a professor at Universit- Laval's School of Psychology. The details of this study are published in the latest edition of the Canadian Journal of Psychiatry.

9 Sep 2010

Multi-resistant CNS bacteria spread in Sweden hospitals

Genetically closely related skin bacteria that have developed resistance to several different antibiotics and that can cause intractable care-related infections are found and seem to be spreading within and between hospitals in Sweden.

9 Sep 2010

Ohio State University receives five-year grant to improve drug therapy using gene profiles

The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

9 Sep 2010

PPD establishes preferred provider relationships for conducting Phase I trials

PPD, Inc. today announced it has established preferred provider relationships with a network of sites across North America for conducting Phase I trials in patients to meet growing client demand for these services.

8 Sep 2010

Bayer Consumer Care introduces One A Day Menopause Formula to help address hot flashes

September is Menopause Awareness Month and women starting the transition into menopause have more information and resources than ever to start taking control of their menopause symptoms. Bayer Consumer Care now introduces One A Day® Menopause Formula, a complete multivitamin with soy isoflavones to help address hot flashes and mild mood changes.

7 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

Studies show diagnostic errors cause adverse events than medication errors

Studies show that diagnostic errors cause twice as many adverse events as medication errors, but the subject has received little attention; Pennsylvania Patient Safety Authority reviews 100 events related to diagnostic error.

3 Sep 2010

Research on motor neuron subtype may provide useful therapy for neuron diseases

Scientists have devised a method for coaxing mouse embryonic stem cells into forming a highly specific motor neuron subtype. The research, published by Cell Press in the September 3rd issue of the journal Cell Stem Cell, provides new insight into motor neuron differentiation and may prove useful for devising and testing future therapies for motor neuron diseases.

3 Sep 2010

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

3 Sep 2010

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."

31 Aug 2010

Central Nervous System News and Research

AACN endorses 'Adult-Gerontology Clinical Nurse Specialist Competencies'

AMRI selects compound for advanced preclinical testing in treatment of IBS

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

ADHD medication improves childhood cancer survivors: Research

Orion extends use of Medidata Rave enterprise-wide EDC and clinical data management system

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

Athersys signs agreement with RTI Biologics for MAPC technology access

Multi-disciplinary team awarded grant to develop interdisciplinary oncology palliative care education program

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Consumption of medications for treatment of insomnia or anxiety increases mortality risk

Multi-resistant CNS bacteria spread in Sweden hospitals

Ohio State University receives five-year grant to improve drug therapy using gene profiles

PPD establishes preferred provider relationships for conducting Phase I trials

Bayer Consumer Care introduces One A Day Menopause Formula to help address hot flashes

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Studies show diagnostic errors cause adverse events than medication errors

Research on motor neuron subtype may provide useful therapy for neuron diseases

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News